Thomas Patrick Kelly

Chief Financial Officer

Deciphera Pharmaceuticals, Inc.Xenon Pharmaceuticals Inc.

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 1 buy · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€493k

▼ Sales (5 ops.)

€130k

Latest filing published 16 Oct 2026 for Xenon Pharmaceuticals Inc.. Read the official filing

Filing timeline

BuySale

Thomas Patrick Kelly

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Xenon Pharmaceuticals Inc. 1 purchase · last 01 Oct 2026

Thomas Patrick Kelly: trading record in brief

Thomas Patrick Kelly (finance chief) discloses dealings in 2 companies, chiefly Deciphera Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. Over a trading history stretching from 15 December 2021 to 15 October 2026, the count stands at 14 filings.

Both buying and selling appear: 1 purchase worth €493k, against 5 sales worth €130k. Netting one side against the other leaves €363k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 7 share grants and 1 option exercise. 2026 to date brings 1 purchase and no sales.

Most recently, on 16 October 2026, the filings show an option exercise in Xenon Pharmaceuticals Inc. The clock since the last published purchase (1 October 2026) now reads 17 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.